Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

STADA 2011 Prelim. Net Profit Falls; Backs Long-term Targets - Quick Facts

STADA Arzneimittel AG (STDAF.PK,STDAY.PK) confirmed its 2011 preliminary results, by reported a plunge in its 2011 net income to 22.0 million euros or 0.37 euros per share from 68.4 million euros or 1.16 euros per share a year ago. However, on an adjusted basis, net profit totaled 146.6 million euros or 2.49 euros per share, higher than last year's 133.3 million euros or 2.27 euros per share.

With varying development in individual national markets, Group sales went up 5% in the reporting year to 1.71 billion euros from 1.63 billion euros in the earlier year period. When effects on sales based on changes in the Group portfolio and currency effects are taken into account, Group sales rose 5% in 2011.

The company said that 2011 reported key earnings figures dropped significantly due to high burdening one-time special effects, mainly as a result of impairments on receivables from various Serbian pharmaceutical wholesalers, operationally, i.e. excluding one-time special effects, however, they all exceeded the key earnings figures, adjusted accordingly, of the prior year.

Despite these earnings burdening one-time special effects from the further implementation of the "STADA - build the future" program, the Executive Board expects a very significant increase in reported net income for 2012 as compared with 2011.

In addition, the Executive Board confirmed its long-term prognosis envisaged for 2014, according to which Group sales of nearly 2.15 billion euros, at an adjusted level, EBITDA of about 430 million euros and net income of around 215 million euros should be reached.

Register
To receive FREE breaking news email alerts for Stada Arzneimittel AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday. Potentially complicating the outlook for control of the Senate, the results of a SurveyUSA poll conducted for WXIA-TV in Atlanta suggest that the Georgia Senate race between Republican David Perdue and Democrat Michelle Nunn could be headed for a runoff.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.